Streetbeat News

Products Services

NIXX

Nixxy shares are trading higher following updates on its business strategy, including acquisitions in traditional markets and improvements in operations through technology and data analytics.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:38 pm

NUZE

NUZEE, Inc. has relocated its U.S. operations from California to Florida and expanded its global presence by establishing offices in Singapore, Hong Kong, Mainland China, and other regions.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:38 pm

BLIN

Bridgeline Digital, Inc. (NASDAQ:BLIN) has announced a significant update to its HawkSearch Rapid UI Framework, incorporating Generative AI to enhance Smart Response capabilities. This update aims to improve eCommerce user experience by enabling interactive conversations and product comparisons within the search interface.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:37 pm

EXLS

EXL (NASDAQ:EXLS) has partnered with Convex Group Limited to enhance operational excellence through data and technology. This multiyear engagement aims to improve efficiency, customer experience, and scalability for Convex, leveraging EXL's expertise in data analytics and AI.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:36 pm

VEEA

Veea has partnered with Inti Cakrawala Teknologi to deliver advanced wireless connectivity and asset tracking solutions for mining operations in Southeast Asia. This initiative aims to enhance worker safety and environmental monitoring, with the first installation set for October 20, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:36 pm

BEAT

HeartBeam has appointed Robert Eno as the new CEO to spearhead U.S. commercialization efforts. The founder, Branislav Vajdic, will transition to the role of President to focus on advancing vector-based technology and AI applications for heart health.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:33 pm

KZR

Kezar Life Sciences announced that the PORTOLA trial of zetomipzomib for autoimmune hepatitis will continue without changes, while the PALIZADE trial for lupus nephritis will be discontinued due to safety concerns. The company will focus on developing zetomipzomib for autoimmune hepatitis.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:32 pm

BNZI

CRM

Banzai has expanded its partnership with Salesforce to enhance its Demio platform, offering features like automated list management, real-time UTM tracking, and advanced search to improve webinar campaigns.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:32 pm

ADIL

Adial Pharmaceuticals has secured a new US patent, expanding its intellectual property protection for its lead drug candidate, AD04, aimed at treating alcohol use disorder. This patent enhances the precision medicine approach by covering additional genotype combinations identified through Adial's genetic diagnostic tool.

Portfolio Pulse from Vandana Singh

October 17, 2024 | 12:30 pm

ADIL

Adial Pharmaceuticals has expanded its patent estate, which covers its unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:30 pm